[go: up one dir, main page]

UY33263A - Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida - Google Patents

Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida

Info

Publication number
UY33263A
UY33263A UY0001033263A UY33263A UY33263A UY 33263 A UY33263 A UY 33263A UY 0001033263 A UY0001033263 A UY 0001033263A UY 33263 A UY33263 A UY 33263A UY 33263 A UY33263 A UY 33263A
Authority
UY
Uruguay
Prior art keywords
sulfonamide
tetrahydroisoquinolina
methylpirrolidin
cyclohexylmetil
etil
Prior art date
Application number
UY0001033263A
Other languages
English (en)
Inventor
Elenbaas Steven
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44012569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY33263A publication Critical patent/UY33263A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un procedimeinto aplicable industrialmente para preparar 2-(ciclohexilmetil)-N-{2-[(2S)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida, y sales de la misma
UY0001033263A 2010-03-05 2011-03-04 Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida UY33263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31106910P 2010-03-05 2010-03-05
FR1059750 2010-11-25

Publications (1)

Publication Number Publication Date
UY33263A true UY33263A (es) 2011-09-30

Family

ID=44012569

Family Applications (2)

Application Number Title Priority Date Filing Date
UY0001033262A UY33262A (es) 2010-03-05 2011-03-04 Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
UY0001033263A UY33263A (es) 2010-03-05 2011-03-04 Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UY0001033262A UY33262A (es) 2010-03-05 2011-03-04 Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida

Country Status (28)

Country Link
US (2) US8748615B2 (es)
EP (2) EP2556064B1 (es)
JP (2) JP2013521308A (es)
KR (2) KR101783679B1 (es)
CN (2) CN103221394A (es)
AR (2) AR080374A1 (es)
AU (2) AU2011222588B2 (es)
BR (2) BR112012022234A2 (es)
CA (2) CA2789669A1 (es)
CL (2) CL2012002451A1 (es)
CO (2) CO6630099A2 (es)
CR (1) CR20120467A (es)
DO (1) DOP2012000228A (es)
EC (1) ECSP12012207A (es)
GT (1) GT201200228A (es)
IL (2) IL221341A (es)
MA (2) MA34144B1 (es)
MX (2) MX2012009413A (es)
NZ (2) NZ601498A (es)
PE (1) PE20130007A1 (es)
PH (2) PH12012501641A1 (es)
RU (2) RU2012142310A (es)
SG (2) SG183256A1 (es)
TN (1) TN2012000361A1 (es)
TW (2) TW201144284A (es)
UY (2) UY33262A (es)
WO (2) WO2011109675A2 (es)
ZA (1) ZA201205311B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida
CN102816101A (zh) * 2012-08-21 2012-12-12 江苏恒祥化工有限责任公司 一种(s)-n-甲基-2氯乙基吡咯烷的合成方法
EP3043799A1 (en) * 2013-09-09 2016-07-20 Sanofi An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
WO2019070827A1 (en) * 2017-10-04 2019-04-11 Celgene Corporation PROCESSES FOR THE PREPARATION OF CIS-4 [2 - {(3S, 4R) -3-FLUOROOXAN-4-YL] AMINO) -8- (2,4,6-TRICHLOROANILINO) -9H-PURIN-9-YL] -1 -MÉTHYLCYCLOHEXANE-1-carboxamide

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228170A (en) 1979-08-30 1980-10-14 Smithkline Corporation 7- and/or 8-Sulfur substituted 1,2,3,4-tetrahydroisoquinoline compounds
US4315935A (en) * 1980-04-14 1982-02-16 Smithkline Corporation N,N'-Bis[substituted-1,2,3,4-tetrahydroisoquinolinolyl]disulfonylimides and antiallergic compositions and method of use
GB8717374D0 (en) 1987-07-22 1987-08-26 Smith Kline French Lab Pharmaceutically active compounds
US4857301A (en) 1987-09-25 1989-08-15 Schering Corporation Sulfonamide compounds, compositions and method of use
AU7102394A (en) 1993-06-09 1995-01-03 Smithkline Beecham Corporation Bicyclic fibrinogen antagonists
GB9322976D0 (en) 1993-11-08 1994-01-05 Pfizer Ltd Therapeutic agents
GB9709303D0 (en) * 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
NZ508101A (en) 1998-04-10 2002-12-20 Japan Tobacco Inc Amidine compounds useful as factor Xa inhibitors and as anticoagulants
GB9816984D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
CA2347095A1 (en) 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Nitrogen-containing condensed heterocyclic derivatives, their production and agent
AU768720B2 (en) 1999-04-01 2004-01-08 Pfizer Products Inc. Aminopyrimidines as sorbitol dehydrogenase inhibitors
GB9912410D0 (en) 1999-05-28 1999-07-28 Pfizer Ltd Compounds useful in therapy
PE20010628A1 (es) 1999-10-01 2001-06-18 Takeda Chemical Industries Ltd Compuestos de amina ciclica, su produccion y su uso
WO2001040192A1 (en) 1999-12-03 2001-06-07 Kyoto Pharmaceutical Industries, Ltd. Novel heterocyclic compounds and salts thereof and medicinal use of the same
FR2804429B1 (fr) 2000-01-31 2003-05-09 Adir Nouveaux derives de 4-sulfonamides piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2807434B1 (fr) 2000-04-05 2002-10-18 Hoechst Marion Roussel Inc Nouveaux derives de la 1,2,3,4-tetrahydroisoquinoleine, leur procede de preparation et leur application comme fongicides
AU9619301A (en) 2000-10-20 2002-04-29 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy
WO2002036560A1 (en) * 2000-10-30 2002-05-10 Warner-Lambert Company Llc Aminoalkylpyrrolidine serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their synthesis
WO2002076925A2 (en) 2001-03-23 2002-10-03 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
WO2002102770A1 (en) * 2001-06-18 2002-12-27 Maruha Corporation Novel aliphatic compound, method of synthesis, and method of utilization
US20050043304A1 (en) 2001-08-01 2005-02-24 Yutaka Kato Novel amine derivative having human beta-tryptase inhibitory activity and drugs containing the same
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
WO2003055848A2 (en) 2001-12-26 2003-07-10 Bayer Healthcare Ag Urea derivatives as vr1- antagonists
US6867224B2 (en) 2002-03-07 2005-03-15 Warner-Lambert Company Compounds that modulate PPAR activity and methods of preparation
AU2004232939A1 (en) 2003-04-17 2004-11-04 Merck Sharp & Dohme Corp. Heterocyclic cyclopentyl tetrahydroisoquinoline and tetrahydropyridopyridine modulators of chemokine receptor activity
FR2857695B1 (fr) 2003-07-15 2007-04-20 Saint Gobain Ct Recherches Bloc pour la filtration de particules contenues dans les gaz d'echappement d'un moteur a combustion interne
WO2005067502A2 (en) 2004-01-02 2005-07-28 Merck & Co., Inc. Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
CN1909906A (zh) 2004-01-20 2007-02-07 默克公司 作为趋化因子受体活性调节剂的2,6－二取代的哌啶类化合物
JP2007534758A (ja) 2004-04-26 2007-11-29 メルク　エンド　カムパニー　インコーポレーテッド ケモカイン受容体活性調節物質であるテトラヒドロピラニルシクロペンチル１−置換及び１，１−二置換テトラヒドロイソキノリン
WO2005120505A2 (en) 2004-04-26 2005-12-22 Merck & Co., Inc Tetrahydropyranyl cyclopentyl tetrahy-dropyridopyridine modulators of chemokine receptor activity
EP1746997A4 (en) 2004-05-11 2010-12-29 Incyte Corp 3- (4-HETEROARYLCYCLOHEXYLAMINE) CYCLOPENTANCARBOXAMIDE AS MODULATORS OF CHEMOKIN RECEPTORS
FR2870846B1 (fr) 2004-05-25 2006-08-04 Sanofi Synthelabo Derives de tetrahydroisoquinolylsulfonamides, leur preparation et leur utilisation en therapeutique
WO2005123089A2 (en) 2004-06-10 2005-12-29 Kalypsys, Inc. Multicyclic sulfonamide compounds as inhibitors of histone deacetylase for the treatment of disease
EP1630158A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
EP1630159A1 (en) 2004-08-18 2006-03-01 Laboratorios Del Dr. Esteve, S.A. 5-HT7 receptor antagonists
SI1809624T1 (sl) 2004-08-28 2014-02-28 Astrazeneca Ab Derivati pirimidinsulfonamida kot modulatorji receptorja kemokina
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
JP5132319B2 (ja) 2004-12-21 2013-01-30 スミスクライン ビーチャム コーポレーション ２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
US20090264425A1 (en) 2004-12-22 2009-10-22 Pfizer Limited Chemical compounds
AU2006208547B2 (en) 2005-01-26 2011-02-10 F. Hoffmann-La Roche Ag Phenyl methanone derivatives and their use as glycine transporter 1 inhibitors
DE102005015040A1 (de) 2005-03-31 2006-10-05 Sanofi-Aventis Deutschland Gmbh Substituierte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
AR053845A1 (es) 2005-04-15 2007-05-23 Tibotec Pharm Ltd 5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
ZA200709961B (en) 2005-05-10 2009-07-29 Vertex Pharma Bicyclic derivatives as modulators of ion channels
EP1911747A1 (en) 2006-10-11 2008-04-16 Laboratorios del Dr. Esteve S.A. Sulfonamide substituted pyrazoline compounds, their preparation and use as CB1 modulators
JP5443975B2 (ja) 2007-04-27 2014-03-19 富山化学工業株式会社 新規なスルホンアミド誘導体またはその塩
CN102036952A (zh) 2008-04-16 2011-04-27 比奥里波克斯公司 用作药物的双芳基化合物
US20100305173A1 (en) 2009-04-30 2010-12-02 Concert Pharmaceuticals, Inc. Hydroxyethylamino sulfonamide derivatives
PL2445899T3 (pl) 2009-06-26 2017-08-31 Sanofi Nowe sole fumaranowe antagonisty receptora histaminy H3
AR080374A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparcion de 2-(ciclohexilmetil)-n-(2-((2s)-1-metilpirrolidin-2-il) etil)- 1,2,3,4-tetrahidroisoquinolin-7- sulfonamida

Also Published As

Publication number Publication date
EP2556064A2 (en) 2013-02-13
CL2012002452A1 (es) 2012-11-30
MX2012008422A (es) 2012-08-15
WO2011109680A2 (en) 2011-09-09
KR101783679B1 (ko) 2017-10-10
CO6630099A2 (es) 2013-03-01
ECSP12012207A (es) 2013-03-28
EP2556064B1 (en) 2014-10-15
PH12012501499A1 (en) 2018-02-07
MA34144B1 (fr) 2013-04-03
IL221339A0 (en) 2012-10-31
US8779145B2 (en) 2014-07-15
CN103221394A (zh) 2013-07-24
PH12012501641A1 (en) 2012-10-22
JP5927126B2 (ja) 2016-05-25
CL2012002451A1 (es) 2012-11-30
ZA201205311B (en) 2013-03-27
AU2011222588B2 (en) 2016-09-08
PE20130007A1 (es) 2013-02-01
BR112012022234A2 (pt) 2015-12-15
US8748615B2 (en) 2014-06-10
CA2787427C (en) 2017-10-10
AR080374A1 (es) 2012-04-04
NZ602009A (en) 2015-01-30
UY33262A (es) 2011-09-30
IL221341A (en) 2014-05-28
EP2542530A2 (en) 2013-01-09
CA2789669A1 (en) 2011-09-09
MA34142B1 (fr) 2013-04-03
AR080375A1 (es) 2012-04-04
RU2012142310A (ru) 2014-04-10
JP2013521309A (ja) 2013-06-10
SG182576A1 (en) 2012-08-30
BR112012022356A2 (pt) 2016-08-30
WO2011109680A3 (en) 2012-12-20
WO2011109675A3 (en) 2012-11-22
JP2013521308A (ja) 2013-06-10
TW201144285A (en) 2011-12-16
US20130137718A1 (en) 2013-05-30
MX2012009413A (es) 2012-09-07
DOP2012000228A (es) 2013-01-15
GT201200228A (es) 2013-11-21
WO2011109675A2 (en) 2011-09-09
US20130123302A1 (en) 2013-05-16
SG183256A1 (en) 2012-09-27
KR20130038186A (ko) 2013-04-17
KR20130047685A (ko) 2013-05-08
TW201144284A (en) 2011-12-16
CN103068815A (zh) 2013-04-24
IL221341A0 (en) 2012-10-31
CR20120467A (es) 2012-10-05
TN2012000361A1 (en) 2014-01-30
RU2012142338A (ru) 2014-04-10
AU2011222588A1 (en) 2012-08-23
CO6630129A2 (es) 2013-03-01
AU2011223560A1 (en) 2012-09-13
NZ601498A (en) 2014-12-24
CA2787427A1 (en) 2011-09-09

Similar Documents

Publication Publication Date Title
CY1124874T1 (el) Διεργασια για την παρασκευη [(5-(3-χλωροφαινυλ)-3-υδροξυπυριδινο-2-καρβονυλ)-αμινο]οξικου οξεος απο 5-((3-χλωροφαινυλ)-3-χλωρο-πυριδιν-2-υλ)-νιτριλιο, και διεργασια για την παρασκευη παραγωγων 5-((αλογονοφαινυλ)-3-αλογονο-πυριδιν-2-υλ)-νιτριλιου
GT201200280A (es) Procedimiento
ECSP11011391A (es) Métodos y productos intermedios para preparar agentes farmacéuticos
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CR20140462A (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil} amino) -1-hidroxietil]-8-hidroquinolin-2(1h)-ona
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
UY33263A (es) Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolina-7-sulfonamida
HK1205095A1 (en) Methods and intermediates for preparing pharmaceutical agents
EA201400475A1 (ru) Способы получения новых производных бензимидазола
CO6480943A2 (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
NI201200127A (es) Procedimiento para la preparación de 2 - ( ciclohexilmetil ) - n - { 2 - [ (2s) - 1 - metilpirrolidin - 2 - il ] etil } - 1, 2, 3, 4 - tetrahidroisoquinolin - 7 - sulfonamida.
EA201301136A3 (ru) Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
UA117900C2 (uk) Спосіб синтезу 3-(2-бром-4,5-диметоксифеніл)пропаннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
HK1180316A (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
HK1178890A (en) Process for the preparation of 2-(cyclohexylmethyl)-n-{2- [(2s)-1-methylpyrrolidin-2-yl]ethyl}-1, 2, 3, 4- tetrahydroisoquinoline-7-sulfonamide
HN2012001859A (es) Procedimiento para la preparacion de 2-(ciclohexilmetil)-n-{2[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
EA201301020A1 (ru) Новый способ синтеза 3-(2-бром-4,5-диметоксифенил)пропаннитрила и применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
ECSP11011547A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3
NI201100210A (es) Nuevas sales de fumarato de un antagonista del receptor de histamina h3.
CY1119348T1 (el) Διαδικασια για την παρασκευη [4,6-δις-διμεθυλαμινο-2- [4- (4-τριφθορομεθυλοβενζοϋλο-αμινο)βενζυλο]πυριμιδιν-5-υλο]οξικου οξεος
UA106380C2 (ru) Фумаратные соли антагониста гистаминового рецептора н3
TH1401006705A (th) วิธีการสำหรับการเตรียม 2-(2,3-ไดเมททิลฟีนิล)-1-โพรพานัล (2-(2,3-dimethylphenyl)-1-propanal)
PL405678A1 (pl) Sposób otrzymywania pochodnych benzimidazolu o aktywności herbicydowej i fungicydowej

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20211014